Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073953 · ClinicalTrials.gov registry record · Phase 1
Primaquine Enantiomers in G6PD Deficient Human Volunteers
A Phase 1 study of G6PD Deficiency, sponsored by University of Mississippi, Oxford.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04073953: Completed Phase 1 study of G6PD Deficiency, sponsored by University of Mississippi, Oxford.
NCT04073953 is a Phase 1 study of G6PD Deficiency that has completed, run by University of Mississippi, Oxford. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04073953, a Phase 1 study of G6PD Deficiency, has completed, sponsored by University of Mississippi, Oxford.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.
Primary Outcome
Change in Methemoglobin concentration in blood from baseline (% hemoglobin)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPQ
- DRUG SPQ
Study Locations (1)
Mississippi
- University of Mississippi - University
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 1 |
What the finished NCT04073953 record still lists
NCT04073953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with G6PD Deficiency appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04073953 reports a single indexed study location in Mississippi.
Frequently Asked Questions
What is clinical trial NCT04073953 about?
NCT04073953 is a clinical study titled "Primaquine Enantiomers in G6PD Deficient Human Volunteers". This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.
What is the current status of trial NCT04073953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-09-01. Estimated completion is 2023-09-01.
What conditions does trial NCT04073953 study?
This clinical trial studies the following conditions: G6PD Deficiency.
What interventions are being tested in trial NCT04073953?
The interventions under investigation include: Placebo (DRUG), RPQ (DRUG), SPQ (DRUG).
Who is sponsoring clinical trial NCT04073953?
This trial is sponsored by University of Mississippi, Oxford, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04073953 being conducted?
This trial has 1 study location across Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for G6PD Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04073953's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI